According to the new market research report “High Content Screening Market by Product (Cell Imaging & Analysis System, Flow Cytometry, Consumable, Software, Service) Application (Primary & Secondary Screening, Toxicity Studies, Target Identification & Validation), End User – Global Forecast to 2022“, published by MarketsandMarkets™,The global high-content screening market is expected to reach USD 909.0 Million by 2022 from USD 557.1 Million in 2017, at a CAGR of 10.3%.
Don’t miss out on business opportunities in “High Content Screening Market”. Speak to our analyst and gain crucial industry insights that will help your business grow: http://bit.ly/2repGgA
Early buyers will receive 10% customization on reports.
The conventional method of toxicity studies involves the screening of large libraries in search of potential drug candidates. This method is expensive, resource- & time-consuming, and has a low success rate. Hence, HCS solutions for testing the potential toxicity of chemicals and complex substances are being adopted by pharmaceutical companies to improve in vitro toxicity testing by reducing the time and cost. The need for cost containment in pharma R&D, advancements in informatics solutions and imaging instruments, and government funding and venture capital investments across developed markets are the major factors driving the growth of the high-content screening (HCS) market. The increasing number of contract research organizations providing HCS outsourcing services, and application of HCS in personalized medicine, present significant growth opportunities in the market. The base year considered for the study is 2016, and the forecast has been provided for the period between 2017 and 2022.
Advancements in informatics solutions and imaging instruments drives the global high content screening market
Over the last few years, the HCS market has witnessed significant developments in the quality of cell imaging instruments and imaging analysis solutions. For instance, the Cell Insight CX7 high-content analysis platform, launched by Thermo Fisher Scientific, Inc. in January 2016, is an integration of wide-field and confocal imaging that enables seven-color excitation and laser autofocus. Moreover, various cell analyzers and cell sorters have also been introduced in the market. In December 2015, Becton, Dickinson and Company launched the BD FACSCelesta cell analyzer that offers the simultaneous measurement of up to 14 different single-cell characteristics. These technologically advanced products have enabled researchers to carry out cell image analysis with increased efficiency and reduced costs.
Browse and in-depth TOC on “High Content Screening Market”
138 – Tables
42 – Figures
166 – Pages
View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/high-content-screening-market-42710391.html
The HCS market is highly competitive in nature. The prominent players in the global high-content screening market are GE Healthcare (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group (Switzerland), BioTek Instruments Inc. (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.).
Request for Free Sample Report @ http://bit.ly/2Qp6gUk
